Virtual Library
Start Your Search
Joshua Robert Rayburn
Author of
-
+
P1.05 - Early Stage NSCLC (ID 691)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.05-012 - Treatment Planning in Non-Small Cell Lung Cancer Shows Variable Utilization of Multidisciplinary Tumor Board (ID 10115)
09:30 - 16:00 | Presenting Author(s): Joshua Robert Rayburn
- Abstract
Background:
With competing treatment options for early stage non-small cell lung cancer (NSCLC), and controversies over patient selection and management of later stage disease, multidisciplinary tumor board (MDTB) is a critical decision-making forum for management plans. Studies encompassing several cancer domains have shown the benefit of MDTBs on operative mortality, 5-year survival, and patient satisfaction. We aimed to determine the timing and utilization of MDTBs, relative to the initiation of treatment, for patients with NSCLC within a large community healthcare system.
Method:
We reviewed cI-III patients who underwent work-up for primary NSCLC during 6/2013-6/2015 in a hospital network of 7 institutions. This network offers mature multidisciplinary care with dedicated thoracic oncologic services collaborating for formal, weekly MDTBs. Only patients who underwent oncologic treatment were included, and were stratified based on initial treatment type: surgical versus chemotherapy (CHT) and/or radiation therapy (RT). Stage was defined as clinical stage established prior to MDTB, or treatment initiation.
Result:
We identified 203 patients; the figure depicts MDTB timing and utilization stratified by stage for each initial treatment type. Sixty seven percent (24/36) of cI patients did not have a MDTB prior to receiving stereotactic ablative radiotherapy (SABR). In addition, 33% (2/6) of the cIII patients did not receive a MDTB prior to surgical resection. Figure 1
Conclusion:
Variable utilization of MDTB was demonstrated for all clinical stages of NSCLC. In cI NSCLC where competing treatment options of surgery and SABR exist, less than half of the patients received multidisciplinary discussion. MDTB was also underutilized in cIII where treatment controversy exists. Although time constraints, referral patterns and provider bias challenge clinical practice, greater study and quality initiatives are necessary to ensure patients have access to MDTB discussion in the rapidly evolving landscape of NSCLC care.
-
+
P1.10 - Nursing/Palliative Care/Ethics (ID 696)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Nursing/Palliative Care/Ethics
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.10-008 - Palliative Care and Hospice Resources are Underutilized in Patients with Advanced Non-Small Cell Lung Cancer (ID 8656)
09:30 - 16:00 | Presenting Author(s): Joshua Robert Rayburn
- Abstract
Background:
The 2010 Temel et al. paper demonstrated a survival benefit from early implementation of palliative care (PC) in stage IV non-small cell lung cancer (NSCLC). Since this finding, medical systems have struggled with the adoption of clinical services for patients with advanced NSCLC, including PC and hospice resources for patients at the end of life. We aimed to document the utilization of PC and hospice resources in NSCLC patients within a large community healthcare system.
Method:
We reviewed a total of 406 stage cI-IV patients who were diagnosed and managed for primary NSCLC during 6/2013-6/2015, in a hospital network of 7 institutions with dedicated PC services. Patients were initially categorized according to the decision to undergo oncologic treatment (therapeutic or palliative) or to receive no oncologic treatment. Patients were further stratified into those who received PC consultation, those referred to hospice (without PC consultation), or those who received neither based on clinical stage.
Result:
We identified 182 stage cIV patients, of which 16% (30/182) received a PC consultation, 39% (71/182) were referred to hospice, and 45% (81/182) received neither. Of the stage cIV patients, those who received oncologic treatment were less likely to receive PC or hospice services (51%, 78/154) than patients without treatment (82%, 23/28); p=0.002 (figure). The figure also demonstrates services utilized by patients of all stages that were ineligible/refused oncologic treatment (48/406). Figure 1
Conclusion:
PC and hospice services were underutilized in patients with advanced disease, and in those likely to reap benefit from these resources. In addition, stage IV patients receiving oncologic treatment were less likely to receive PC or hospice services than patients undergoing no oncologic treatment. Quality improvement interventions and referral triggers targeting the implementation of PC and hospice services early in patient management are needed to meet patient’s global oncologic needs.
-
+
P3.13 - Radiology/Staging/Screening (ID 729)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiology/Staging/Screening
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.13-029 - Imaging Guideline-Recommendations Prior to Treatment for Non-Small Cell Lung Cancer Demonstrates Variable Compliance (ID 10121)
09:30 - 16:00 | Presenting Author(s): Joshua Robert Rayburn
- Abstract
Background:
Poor adherence to the recommended guidelines in diagnosing and staging patients with non-small cell lung cancer (NSCLC), with negative downstream effects has been previously shown. In addition, studies have demonstrated benefits of staging with PET, including a reduction in number of non-curative resections performed and a higher rate of identifying M1b disease. Staging with brain MRI has demonstrated a yield up to 10% for detecting metastasis in patients with negative clinical examinations. We aimed to assess the adherence to imaging guidelines for PET and brain MRI in the staging of NSCLC patients prior to treatment within our healthcare system.
Method:
We reviewed patients who underwent initial work-up for primary NSCLC during 6/2013–6/2015, in a hospital network of 7 institutions. Clinical stage II-IV patients were stratified by imaging performed prior to the initiation of treatment. Evidence-based clinical practice guidelines referenced include the American College of Chest Physicians (ACCP) 3[rd] edition and the National Comprehensive Cancer Network (NCCN) 7[th] version. Both ACCP and NCCN recommend a PET scan for suspected cIb-III; while ACCP recommends a brain MRI for suspected cIII-IV, and NCCN for suspected cIb-IV.
Result:
The figure demonstrates compliance rates for the 283 included patients. Of cII patients, 7% (2/30) did not receive a PET scan and 43% (13/30) did not receive a brain MRI; while, 11% (6/56) of cIII did not receive a PET scan and 20% (11/56) did not receive a brain MRI. Figure 1
Conclusion:
Variable compliance with imaging guidelines for the use of PET and brain MRI imaging for the staging of our NSCLC patients was seen. Lack of appropriate imaging for NSCLC staging may lead to inappropriate management decisions resulting from incomplete staging information. Quality initiatives are necessary to ensure guideline compliance.
